Stents: Abbott's Xience Xpedition wins CE Mark

Abbott [1] (NYSE:ABT [2]) said its Xience Xpedition coronary stent won CE Mark approval in Europe, with an immediate launch slated for all countries that recognize the mark.

The Chicago-area medical device company said the Xience Xpedition is approved to treat patients with diabetes and requires only 3 months of dual-antiplatelet drug therapy, which Abbott touted as "the shortest duration required for any major drug eluting stent offered in Europe," according to a press release.